Echo Therapeutics

Newsroom

Thu, 18 Feb 2010 17:44:51 Z

<% style_additions '#middle_column li {margin-bottom: 6px; }' %>

Newsroom

Press Releases

February 18, 2010
Echo Therapeutics Announces Significant Product Development Milestone: The Completion of Next Generation Electronic Components for its Revolutionary, Patented Symphony tCGM System
February 9, 2010
Echo Therapeutics Chairman and CEO to be Interviewed on Steve Crowley's American Scene Radio Program and Featured on Money Channel Inc.
January 22, 2010
Echo Therapeutics Announces Research Initiation by LifeTech Capital
January 19, 2010
Echo Therapeutics Chairman and CEO to be Interviewed on Steve Crowley's American Scene Radio Program and Featured on Money Channel Inc.
January 11, 2010
Echo Therapeutics Announces Major Milestone: The Completion of Product Development Work of its Revolutionary, Patented Prelude SkinPrep System
January 7, 2010
Echo Therapeutics to Present at OneMedForum 2010 Emerging Company Finance Conference
January 5, 2010
Echo Therapeutics CEO Interviewed by Stockgoodies.com
Patrick Mooney Discusses Transformative Year, Development Progress and Growth Strategy
December 29, 2009
Echo Therapeutics Provides Business Update
Building on Product Development Sucesses in 2009, Management Reiterates Expectation That 2010 Will Represent a Transformative Year
December 10, 2009
Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign
November 24, 2009
Echo Therapeutics to Present at the New York Society of Analysts' 13th Annual Biotech and Specialty Pharmaceuticals Conference
November 19, 2009
Echo Therapeutics Announces Positive Results of a Clinical Study Testing Symphony tCGM System in Patients with Type 1 and Type 2 Diabetes
November 4, 2009
Echo Therapeutics Initiates Clinical Study of Its New One-Piece Symphony tCGM Biosensor in Type 1 and Type 2 Diabetic Patients
October 29, 2009
Echo Therapeutics Announces Significant Advance in Development of Its One-Piece Needle Free Symphony tCGM Biosensor
October 1, 2009
Echo Therapeutics to Present at 4th Annual JMP Securities Healthcare Conference
September 3, 2009
Echo Therapeutics to Present at Rodman & Renshaw 2009 Annual Global Investment Conference
July 20, 2009
Echo Therapeutics to Present at Jessup & Lamont 2009 Growth Stock Conference
July 9, 2009
Echo Therapeutics to Present at Prestigious “Innovations in Diabetes” Conference
June 17, 2009
Echo Therapeutics and Handok Pharmaceuticals Sign South Korea License for Needle-free Symphony™ Transdermal Continuous Glucose Monitoring System
May 28, 2009
Echo Therapeutics Licenses Needle-free Prelude SkinPrep System to Ferndale Pharma for Enhanced Delivery of Topical Lidocaine
November 13, 2008
Echo Therapeutics to Present Clinical Study Results of Its Symphony Transdermal Continuous Glucose Monitoring System at Annual Diabetes Technology Meeting
November 6, 2008
Echo Therapeutics to Present at Rodman & Renshaw’s Annual Global Investment Conference
October 16, 2008
Echo Therapeutics Announces Issuance of New Patent for Symphony™ Transdermal Continuous Glucose Monitoring System
October 2, 2008
Echo Therapeutics to Present at JMP Securities Healthcare Investor Conference
July 29, 2008
Echo Therapeutics Announces Positive Results of a Clinical Study of its Symphony™ Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes
July 14, 2008
Echo Therapeutics Announces Publication of Positive Clinical Data for its Symphony™ Transdermal Continuous Glucose Monitoring System in Journal of Diabetes Science and Technology
July 1, 2008
Echo Therapeutics Initiates Clinical Study of Its Symphony™ Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes
May 6, 2008
Dr. Anthony P. Furnary Joins Echo Therapeutics Medical Advisory Board
April 28, 2008
Echo Therapeutics and Cato BioVentures Sign Right of First Offer Agreement for
Dermatology Products and Transdermal Drug Delivery Technologies
April 9, 2008
Echo Therapeutics Announces Positive Results with the Prelude™ SkinPrep System, the Next-Generation Skin Permeation Medium for its Symphony™ Transdermal Continuous Glucose Monitoring System
Marth 25, 2008
Echo Therapeutics Announces Agreement for $2,000,000 Debt Financing
March 13, 2008
Echo Therapeutics Announces Positive Results from Symphony ™ Transdermal Continuous Glucose Monitoring System Study at Tufts Medical Center
February 12, 2008
Echo Therapeutics Announces Closing of Approximately $2.3 Million Private Financing
February 4, 2008
Echo Therapeutics to Present at RedChip Small-Cap Investor Conference
January 2, 2008
Echo Therapeutics Starts Clinical Study of Its Symphony™ Continuous Transdermal Glucose Monitoring System
November 20, 2007
Echo Therapeutics Reports Third Quarter 2007 Results
October 5, 2007
Sontra Medical Corporation Changes Name to Echo Therapeutics, Inc.
September 17, 2007
Sontra Medical and Echo Therapeutics Announce Merger
June 18, 2007
Sontra Medical Corporation Closes $1,000,000 Financing
May 8, 2007
Sontra Announces OTC Bulletin Board Quotation.
March 30, 2007
Sontra Medical Reports Fourth Quarter and Fiscal Year 2006 Results and Business Update.
February 21, 2007
Sontra Medical Appoints New Board Member.
January 30, 2007
Sontra Medical Corporation Closes $660,000 Financing.
January 3, 2007
Sontra Enters into Agreement for $600,000 Equity Investment.
Prior
Press Release Archive

Welcome

Fri, 12 Feb 2010 16:26:34 Z

Welcome

<%= no_cache %>

You are now logged in to <%= config_site_name %>as ‘<%= session_user_name %>’ with role ‘<%= session_role_name %>’.

<% if user_info_incomplete %>

Updating Your Information

Your information is not complete. Please take a moment to update your account information .

<% end %>

Directors

Wed, 20 Jan 2010 21:16:51 Z

Directors

Non-Management

Walter W. Witoshkin

Mr. Witoshkin joined the Board of Sontra Medical Corporation (now Echo) in February 2007. He has served as Chairman and Chief Executive Officer of QuantRx Biomedical Corporation (OTCBB: QTXB) since 2005. A 40-year veteran of the pharmaceutical, healthcare and biomedical industries, Mr. Witoshkin has held senior executive positions at leading healthcare product and pharmaceutical companies, most recently SmithKline Beecham, now Glaxo SmithKline, where he was Vice President of Business Development and Chief Financial Officer. In 1989, Mr. Witoshkin established Menley & James Laboratories, Inc., after purchasing 32 SmithKline Beecham over-the-counter pharmaceutical and toiletry product brands. Menley & James had its initial public offering in 1992. He earlier held several senior finance positions at American Cyanamid, which became American Home and then Wyeth. Mr. Witoshkin joined QuantRx from Trident Group LLC, global operational consultants to the pharmaceutical and related healthcare industries. As a founding partner of Trident Group, Mr. Witoshkin specialized in alternative sourcing for manufacturing and the acquisition of technologies and products.

Vincent D. Enright

Mr. Enright joined our Board of Directors in March 2008. He has more than 30 years of financial experience with public companies, including as Senior Vice President and Chief Financial Officer of KeySpan Corporation, a NYSE public utility company. Mr. Enright currently serves as a director and Audit Committee Chairman of certain of the funds managed by Gabelli Funds, LLC, a leading mutual fund manager, positions he has held since 1991. Mr. Enright holds a B.S. degree in Accounting from Fordham.

Shawn K. Singh, JD

Mr. Singh joined Echo's Board of Directors in September 2007 as a result of the merger of Sontra Medical Corporation and Echo Therapeutics, Inc., for which he served as Chairman of the Board from September 2006 through the date of the merger and as President and director from September 2004 to September 2006. Mr. Singh has been working with life science companies for nearly 20 years. In addition to his role on Echo's Board of Directors, Mr. Singh currently serves as Chief Executive Officer of VistaGen Therapeutics. He also serves as a strategic advisor to Cato BioVentures, of which he served as Managing Principal from 2001 through August 2009. Mr. Singh began his career as a Corporate Finance Associate in the Silicon Valley offices of Morrison & Foerster. He later served as Chief Business Officer of SciClone Pharmaceuticals (Nasdaq: SCLN), Chief Business Officer and General Counsel of Cato Research Ltd., a global contract research and development organization, President of Artemis Neuroscience, and Chief Executive Officer of Hemodynamic Therapeutics. Mr. Singh received his B.A., with honors, from the University of California, Berkeley, and his J.D. from The University of Maryland School of Law.

Management

Patrick T. Mooney MD, CEO, President and Chairman of the Board

Dr. Mooney joined Echo in September 2007 as a result of the merger of Sontra Medical Corporation and then privately-held Echo Therapeutics, Inc. (ETI), for which he served as President, Chief Executive Officer and director from September 2006 through the date of the merger. Prior to joining ETI, Dr. Mooney was President, Chief Executive Officer and Chairman of Aphton Corporation (Nasdaq: APHT), where he had also served as Chief Medical Officer. Prior to that, Dr. Mooney served as Vice President, Senior Biotechnology Analyst at Thomas Weisel Partners, LLC, a full service merchant banking firm and as Vice President, Senior Biotechnology Analyst at Janney Montgomery Scott, LLC, a full services investment banking firm. Dr. Mooney received his medical degree from the Jefferson Medical College of Thomas Jefferson University and trained in surgery at Thomas Jefferson University Hospital.

Corporate Info

Wed, 20 Jan 2010 21:13:57 Z

Corporate Information

Board of Directors

Non-Management Members

Vincent D. Enright

Walter W. Witoshkin

Shawn K. Singh, JD

Management Members

Patrick T. Mooney, MD

SEC Form 10-K

Echo's Annual Report on Form 10-K for the fiscal year ended December 31, 2008 is available free of charge by writing to:

Harry G. Mitchell
COO and CFO
Echo Therapeutics, Inc.
10 Forge Parkway
Franklin, MA 02038
<%= email 'hmitchell@echotx.com' %>

Form 10-K For Year Ended December 31, 2008

Annual Meeting

Echo's 2009 Annual Meeting of Shareholders was held on July 8, 2009, at 4:00 p.m. at the offices of Drinker Biddle Reath LLP., located at One Logan Square, 1800 Cherry Street, Philadelphia, Pennsylvania.

Proxy Statement

Transfer Agent and Registrar

Wells Fargo Shareowner Services
161 North Concord Exchange
South St. Paul, MN 55075
800.689.8788 - Telephone

Independent Auditors

Wolf & Company, P.C.
99 High Street
Boston, MA 02110

Echo At a Glance

Thu, 19 Nov 2009 20:20:51 Z

Echo At A Glance

Core Business:	Echo Therapeutics is a medical device and specialty pharmaceutical company developing a non-invasive (needle-free), wireless, transdermal continuous glucose monitoring (tCGM) system for people with diabetes and for use in hospital critical care units, as well as a wide range of topical reformulations of pharmaceutial products previously approved by the United States Food and Drug Administration.
Headquarters:	Echo Therapeutics, Inc. 10 Forge Parkway Franklin, MA 02038 USA 508.553.8850 - Telephone 508.553.8760 - Fax
CEO, President & Chairman:	Patrick T. Mooney, MD
COO & CFO:	Harry G. Mitchell, CPA
OTCBB Symbol:	ECTE
Shares Outstanding:	Approximately 26.75 million
Fiscal Year End:	December 31
Core Technologies:	Echo's Symphony™ tCGM System is a non-invasive (needle-free), wireless, tCGM system for people with diabetes and for use in hospital critical care units. Symphony includes the Prelude™ SkinPrep System that incorporates Echo's patented feedback mechanism for optimal, safe control of skin ablation and its non-invasive transdermal biosensor technologies. With Symphony, Echo is focused on providing reliable, on-demand glucose data continuously, conveniently and cost-effectively. Echo's goal is to change the current paradigm of invasive, episodic glucose testing for people with diabetes and for use in hospital critical care settings with a reliable, needle-free and easy-to-use tCGM system that can provide continuous tracking and trending of glucose levels throughout the day and night. Echo is leveraging it AzoneTS™ skin ablation technology to develop a wide-variety of new transdermal reformulations of pharmaceutical products previously approved by the FDA. Echo has submitted a New Drug Application (NDA) to the FDA covering its lead AzoneTS-reformulated product candidate, Durhalieve™, for treatment of corticosteroid responsive dermatoses. Echo is also focused on Phase 2 development of Durhalieve for keloid scarring. Echo is developing additional AzoneTS™ product candidates in accordance with the FDA's Section 505(b)(2) guidelines.
Transfer Agent & Registrar:	Wells Fargo Shareowner Services 161 North Concord Exchange South St. Paul, MN 55075 800.689.8788 - Telephone
Independent Auditors:	Wolf & Company, P.C. 99 High Street Boston, MA 02110
General Business Inquiries:	Patrick T. Mooney, MD CEO, President and Chairman of the Board 508.553.8850 - Telephone 508.553.8760 - Fax <%= email 'pmooney@echotx.com' %>
	(The information above is current as of May 15, 2009)

About Echo

Thu, 22 Oct 2009 16:11:57 Z

About Echo

Echo Therapeutics is focused on transdermal continuous glucose montioring (tCGM) systems for people with diabetes and advanced topical reformulations of FDA-approved specialty pharmaceuticals.

Echo's Symphony™ tCGM System is a non-invasive (needle-free), wireless, transdermal continuous glucose monitoring (tCGM) system in development for people with diabetes and for use in hospital critical care units. Symphony includes the Prelude™ SkinPrep System that incorporates Echo's patented feedback mechanism for optimal skin ablation control and its non-invasive, continuous transdermal biosensor. With Symphony, Echo is focused on changing the paradigm of invasive, episodic glucose testing for people with diabetes and for use in hospital critical care settings with technology designed to assist clinical professionals, improve patient compliance and achieve better overall glucose control.

Echo is leveraging its patented AzoneTS™ transdermal drug reformulation technology to build a pipeline of novel topical reformulations of FDA-approved products. Echo is developing most of its AzoneTS pipeline in accordance with the FDA's Section 505(b)(2) guidelines. Durhalieve™, Echo's lead AzoneTS drug candidate, is an AzoneTS topical reformulation of triamcinolone acetonide. Echo has submitted a New Drug Application (NDA) to the FDA covering Durhalieve as a new, proprietary treatment for corticosteroid responsive dermatoses. Echo is planning to submit an Investigational New Drug (IND) application to the FDA to commence Phase 2 clinical development of Durhalieve for treatment of keloid scarring and hypertrophic scarring.

Help-Adding a Press Release

Thu, 03 Sep 2009 17:31:18 Z

Help - Adding a Press Release

Save the press release as a PDF file
Login to the Echotx Site if not already logged in
Go to the Newsroom page and click "Edit Page" at the bottom
Choose "File Upload" at the bottom under Plugins
Browse for the file, then Upload it
Right-click on the filename and choose "Copy Shortcut" (for IE, for Firefox it is called "Copy Link Location")
Go to the top and put the cursor between the dot and the existing press release and press the Enter key
Type the date
Press Shift-Enter
Type (or copy) the name of the press release
Select the name of the press release
In the edit window toolbar, choose the "Insert/Edit Link" button (Looks like a world with a link in front)
Change the "Link Type" to "URL"
Put the cursor in the "URL" field and Ctrl-V to paste in the press release link
Select the "Target" tab
Under the "Target" drop-down, select "New Window (_blank)"
Select Ok
Select the Save button

Employment

Tue, 07 Jul 2009 19:47:53 Z

Employment Opportunities

Careers at Echo

Thank you for your interest in career opportunities at Echo. People are the core of our business, and we offer challenging opportunities for individuals interested in diverse career options and a dynamic working environment. We employ or plan to employ qualified professionals in many areas from the medical device and pharmaceutical industries, including research, development, medical/clinical affairs, regulatory affairs, manufacturing, packaging, quality control and assurance, marketing, sales, finance and administration.

Echo is an equal opportunity employer which recruits, hires, trains and promotes persons in all positions without regard to race, color, religion, sex, national origin, citizenship, disability or veteran status.

Current Opportunities

Although we currently do not have any open positions, we welcome you to provide us with your resume for future consideration at <%= email 'HRJobs@echotx.com' %>.

Partnering

Tue, 07 Jul 2009 18:15:34 Z

Strategic Partnering Opportunities

Echo owns all rights to its new Symphony™ tCGM System and Prelude™ SkinPrep System. Symphony and Prelude represent valuable, multiple-market partnering and licensing opportunities for companies with a presence in the diabetes home use market care or in a hospital acute care markets.

Echo offers a medical device platform for transdermal glucose monitoring and for opportunities in transdermal drug delivery. Echo's AzoneTS™ transdermal reformulation platform, patented through 2019, offers reformulation opportunities for products previously approved by the FDA. AzoneTS is a valuable life-cycle management asset for line-extensions of existing products and a renewable source of advanced formulations of FDA-approved drugs. Echo expects most of its AzoneTS pipeline programs to be amenable to the FDA's Section 505(b)(2) guidelines.

Conference Calls

Tue, 07 Jul 2009 16:59:10 Z

<% style_additions '#middle_column li {margin-bottom: 6px; }' %>

Conference Calls

Management

Tue, 07 Jul 2009 16:58:32 Z

Management

Patrick T. Mooney MD, CEO, President and Chairman of the Board

Dr. Mooney joined Echo in September 2007 as a result of the merger of Sontra Medical Corporation and then privately-held Echo Therapeutics, Inc. (ETI), for which he served as President, Chief Executive Officer and director from September 2006 through the date of the merger. Prior to joining ETI, Dr. Mooney was President, Chief Executive Officer and Chairman of Aphton Corporation (Nasdaq: APHT), where he had also served as Chief Medical Officer. Prior to that, Dr. Mooney served as Senior Biotechnology Analyst at Thomas Weisel Partners, LLC, a full service merchant banking firm and as Senior Biotechnology Analyst at Janney Montgomery Scott, LLC, a full services investment banking firm. Dr. Mooney received his medical degree from the Jefferson Medical College of Thomas Jefferson University and trained in surgery at Thomas Jefferson University Hospital.

Harry G. Mitchell, Chief Operating Officer and Chief Financial Officer

Mr. Mitchell joined Sontra Medical Corporation (now Echo) in June 2006 and served as Sontra's Interim Chief Executive Officer and Chief Financial Officer commencing in January 2007 through its merger with ETI. Prior to joining Sontra, Mr. Mitchell served as President and Chief Executive Officer of MedTech Advances, Inc., a privately-held diabetes medical device company, Executive Vice President and a director of Boston Medical Technologies, Inc., a privately-held diabetes medical device company, and as a financial and management consultant to several other public and private companies. Mr. Mitchell is a member of the American Institute of Certified Public Accounts and the Massachusetts Society of Certified Public Accountants.

HomePage

Tue, 30 Jun 2009 21:22:33 Z

<% full_page %><% style_additions '#middle_column {border-left: 0; padding-left: 0; padding-right: 0;} .middle_column_full { width: 800px; }' %>

Making a difference

Echo Therapeutics is a transdermal medical device and specialty pharmaceuticals company.

Echo's Symphony™ tCGM System is a non-invasive (needle-free), wireless, transdermal continuous glucose monitoring (tCGM) system focused on changing the paradigm of invasive, episodic glucose testing in diabetes home use and hospital critical care markets.

Echo's AzoneTS™ transdermal drug reformulation technology is focused on building a pipeline of safer and improved versions of widely-prescribed, FDA-approved specialty pharmaceutical products. Echo is developing most of its AzoneTS pipeline in accordance with the FDA's Section 505(b)(2) guidelines. Durhalieve™, Echo's lead AzoneTS drug candidate, is an advanced topical reformulation of triamcinolone acetonide for treatment of corticosteroid responsive dermatoses. Echo has submitted its Durhalieve New Drug Application (NDA) to the FDA .

Contact Us

Tue, 30 Jun 2009 21:18:33 Z

Contact Info

Boston Area Office

10 Forge Parkway
Franklin, MA 02038
508-553-8850 - Telephone
508-553-8720 - Fax
www.echotx.com

Key Strategic Partners

Tue, 30 Jun 2009 21:18:09 Z

Strategic Relationship with Cato Research and Cato BioVentures

Echo has a strategic development relationship with Cato Research, a leading contract research and development organization (CRO) with over 300 employees worldwide. Cato Research is the core portfolio company of Cato BioVentures, a life science venture capital firm and an institutional shareholder of Echo. Due to its strategic affiliation with Cato BioVentures and its extensive expertise working with Echo's AzoneTS reformulation platform, Echo has unique strategic access to a wide range of CRO services from Cato Research to support several of its regulatory programs. Accordingly, Echo expects its AzoneTS product development activities to be heavily based on flexible, real-time strategic outsourcing to Cato Research and other vendors and contract service providers in the pharmaceutical industry. Additionally, Echo's strategic access to Cato Research's pharmaceutical industry client base provides Echo with unique access to a network of prospective pharmaceutical partners with interest in development and commercialization of specialty pharmaceuticals and diabetes management products.

Business Overview

Tue, 30 Jun 2009 21:15:28 Z

Business Overview

Echo Therapeutics (OTCBB: ECTE) is developing its Symphony™ tCGM System, a novel, non-invasive (needle-free), wireless, transdermal continuous transdermal glucose monitoring (tCGM) system for people with diabetes and for use in hospital critical care units, and a pipeline of specialty pharmaceutical products incorporating its proprietary AzoneTS™ transdermal drug reformulation technology.

Echo is leveraging its unique, long-term strategic development relationship with Cato Research, a global contract research and development organization (CRO) and an affiliate of Echo's largest institutional investor, Cato BioVentures, to develop its pharmaceutical pipeline efficiently and cost-effectively.

Echo Therapeutics

Newsroom

Newsroom

Press Releases

Welcome

Welcome

Updating Your Information

Editing a Page

Directors

Directors

Non-Management

Walter W. Witoshkin

Vincent D. Enright

Shawn K. Singh, JD

Management

Patrick T. Mooney MD, CEO, President and Chairman of the Board

Corporate Info

Corporate Information

Board of Directors

Non-Management Members

Management Members

SEC Form 10-K

Annual Meeting

Transfer Agent and Registrar

Independent Auditors

Echo At a Glance

Echo At A Glance

About Echo

About Echo

Help-Adding a Press Release

Help - Adding a Press Release

Employment

Employment Opportunities

Careers at Echo

Current Opportunities

Partnering

Strategic Partnering Opportunities

Conference Calls

Conference Calls

Management

Management

Patrick T. Mooney MD, CEO, President and Chairman of the Board

Harry G. Mitchell, Chief Operating Officer and Chief Financial Officer

HomePage

Making a difference

Contact Us

Contact Info

Boston Area Office

Key Strategic Partners

Strategic Relationship with Cato Research and Cato BioVentures

Business Overview

Business Overview